MC
ADPT icon

Maverick Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Maverick Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,315
Closed -$93K – 665
2021
Q1 		$93K Buy
+2,315
New +$125K ﹤0.01% 592

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Maverick Capital's ADPT Position: Q2 2021 in Review

Maverick Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 2,315 shares — an estimated $93K sold.

Maverick Capital first reported a position in ADPT in Q1 2021 and held it in 1 quarter. The position peaked at $93K in Q1 2021. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • Maverick Capital reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Maverick Capital sold 2,315 Adaptive Biotechnologies shares in Q2 2021, an estimated $93K.
  • Maverick Capital first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 1 quarter.
  • Maverick Capital's Adaptive Biotechnologies position peaked at $93K in Q1 2021.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.